
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc reported strong third-quarter revenues of $136.1 million, surpassing consensus estimates and demonstrating a robust year-over-year growth of 69% and a quarter-over-quarter increase of 14%. The improvement in payer coverage to 85% and a significant advance in commercial coverage to 75% following a new third-party contracting agreement indicate a favorable regulatory environment, supporting further sales growth. With projected revenue growth outpacing operating costs, the company anticipates becoming cash flow positive in 2026, driven by its innovative product pipeline and solid management strategies.
Bears say
Axsome Therapeutics Inc. experienced a setback as its Phase 3 PARADIGM study for major depressive disorder (MDD) failed to meet overall efficacy endpoints, despite showing statistically significant results in a prespecified subset of patients with excessive daytime sleepiness (EDS). This failure raises concerns about the company's ability to differentiate its treatments in a competitive market, as the differentiation relies heavily on the impact demonstrated in the roughly 50% of the MDD population that experiences EDS. Furthermore, the need to initiate a new Phase 3 study in this specific subset of MDD patients poses additional financial uncertainties and potential delays in bringing its therapies to market.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares